Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial

• Published in: PLoS medicine Vol. 6; no. 6; p. e1000104
• Main Authors: Eddleston, Michael, Eyer, Peter, Worek, Franz, Juszczak, Edmund, Alder, Nicola, Mohamed, Fahim, Senarathna, Lalith, Hittarage, Ariyasena, Azher, Shifa, Jeganathan, K, Jayamanne, Shaluka, von Meyer, Ludwig, Dawson, Andrew H, Sheriff, Mohamed Hussain Rezvi, Buckley, Nick A
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30-06-2009; Public Library of Science (PLoS)
• Subjects: Acetylcholinesterase - metabolism; Adult; Antidotes - adverse effects; Antidotes - pharmacokinetics; Antidotes - therapeutic use; Atropine - pharmacology; Critical Care and Emergency Medicine; Drug Therapy, Combination; Female; Humans; Insecticides - poisoning; Intubation, Intratracheal; Male; Organoplatinum Compounds - poisoning; Poisoning - mortality; Pralidoxime Compounds - adverse effects; Pralidoxime Compounds - pharmacokinetics; Pralidoxime Compounds - therapeutic use; Antidotes; Humans; Organoplatinum Compounds; Insecticides; Male; Acetylcholinesterase; Atropine; Adult; Female; Poisoning; Drug Therapy, Combination; Intubation, Intratracheal; Pralidoxime Compounds
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1000104

Poisoning with organophosphorus (OP) insecticides is a major global public health problem, causing an estimated 200,000 deaths each year. Although the World Health Organization recommends use of pralidoxime, this antidote's effectiveness remains unclear. We aimed to determine whether the addition of pralidoxime chloride to atropine and supportive care offers benefit.
We performed a double-blind randomised placebo-controlled trial of pralidoxime chloride (2 g loading dose over 20 min, followed by a constant infusion of 0.5 g/h for up to 7 d) versus saline in patients with organophosphorus insecticide self-poisoning. Mortality was the primary outcome; secondary outcomes included intubation, duration of intubation, and time to death. We measured baseline markers of exposure and pharmacodynamic markers of response to aid interpretation of clinical outcomes. Two hundred thirty-five patients were randomised to receive pralidoxime (121) or saline placebo (114). Pralidoxime produced substantial and moderate red cell acetylcholinesterase reactivation in patients poisoned by diethyl and dimethyl compounds, respectively. Mortality was nonsignificantly higher in patients receiving pralidoxime: 30/121 (24.8%) receiving pralidoxime died, compared with 18/114 (15.8%) receiving placebo (adjusted hazard ratio [HR] 1.69, 95% confidence interval [CI] 0.88-3.26, p = 0.12). Incorporating the baseline amount of acetylcholinesterase already aged and plasma OP concentration into the analysis increased the HR for patients receiving pralidoxime compared to placebo, further decreasing the likelihood that pralidoxime is beneficial. The need for intubation was similar in both groups (pralidoxime 26/121 [21.5%], placebo 24/114 [21.1%], adjusted HR 1.27 [95% CI 0.71-2.29]). To reduce confounding due to ingestion of different insecticides, we further analysed patients with confirmed chlorpyrifos or dimethoate poisoning alone, finding no evidence of benefit.
Despite clear reactivation of red cell acetylcholinesterase in diethyl organophosphorus pesticide poisoned patients, we found no evidence that this regimen improves survival or reduces need for intubation in patients with organophosphorus insecticide poisoning. The reason for this failure to benefit patients was not apparent. Further studies of different dose regimens or different oximes are required.